jag1b Antibody

Introduction to JAG1 Antibodies

JAG1 antibodies are monoclonal antibodies (mAbs) designed to neutralize the JAG1 protein, a ligand in the Notch signaling pathway. JAG1 is a transmembrane glycoprotein with a Delta/Serrate/Lag2 (DSL) domain critical for binding Notch receptors . Dysregulated JAG1-Notch signaling is implicated in cancer progression, stem cell maintenance, and pathological angiogenesis, making it a therapeutic target .

Development and Epitope Specificity

Key JAG1-neutralizing antibodies include:

• Epitope Mapping: Antibodies like J1-65D and J1-183D bind the DSL domain, with E228D substitution abolishing murine reactivity .

• Cross-Reactivity: J1-142B binds murine Jag1 but was excluded due to lower efficacy .

Mechanism of Action

JAG1 antibodies inhibit Notch signaling through:

1. Blocking Receptor-Ligand Interaction: Antibodies prevent JAG1-Notch binding, confirmed via FACS and Surface Plasmon Resonance .

2. Downstream Signaling Suppression: Reduces Hes1 and Hey1 transcription factors, markers of Notch activation .

3. Targeting Tumor-Stroma Crosstalk: Dual targeting of tumor and stromal JAG1 enhances efficacy in xenograft models .

Key Functional Outcomes

• 3D Cancer Spheroid Growth: JAG1 antibodies reduced spheroid size and cancer stem cell markers (e.g., CD44+/CD24−) in breast cancer models .

• Metastasis Inhibition: In rat models of triple-negative breast cancer brain metastasis, treatment decreased tumor growth by 60% and improved blood-brain barrier function via MRI .

• Microglial Modulation: Anti-JAG1.b70 (murine cross-reactive) reduced IBA-1+ microglia by 60% in choroidal neovascularization models .

Clinical Implications

• Safety Profile: No detectable toxicity in preclinical models .

• Therapeutic Potential: Combines anti-tumor and anti-angiogenic effects, particularly in stromal-rich environments .